Merck China’s Strategic Push Aligns with Beijing’s 15th Five‑Year Plan

As Shanghai prepares to host the 9th China International Import Expo (CIIE) from 5 to 10 November, the city once again becomes a focal point for foreign firms seeking to navigate China’s evolving economic landscape. In a recent interview on CGTN’s programme “The Hub,” Wang Guan sat down with Rogier Janssens, president of Merck China and managing director of Merck Life Science China, to discuss how the German‑based multinational is calibrating its long‑term investment strategy to the contours of China’s 15th Five‑Year Plan. The conversation illuminated three intersecting themes: Merck’s commitment to deepening its presence in China, its integration with the nation’s burgeoning innovation ecosystem, and the growing relevance of artificial intelligence (AI) in biotechnology and cancer treatment. By situating these corporate priorities within the broader policy framework of “high‑quality development,” the interview offers a window into how leading foreign enterprises are interpreting Beijing’s strategic signals and positioning themselves for the next phase of Sino‑global economic engagement.

China’s 15th Five‑Year Plan: A Blueprint for High‑Quality Development

The 15th Five‑Year Plan, unveiled earlier this year, marks a decisive shift from the quantitative growth model that characterised earlier planning cycles toward a qualitative, “high‑quality” development agenda. Central to the plan is the emphasis on technological self‑reliance, the expansion of the domestic innovation ecosystem, and the cultivation of a modern industrial chain that integrates digitalisation, green technologies, and advanced manufacturing. The policy documents stress that foreign investment will continue to be welcomed, provided it aligns with the nation’s strategic priorities and contributes to the upgrading of domestic capabilities.

Within this context, the CIIE serves as a showcase for the import‑export balance that the plan seeks to optimise. The expo’s theme this year—highlighting “global cooperation for a shared future”—mirrors Beijing’s diplomatic messaging that foreign partners are essential to the country’s high‑quality development trajectory. For multinational corporations, the expo is not merely a trade fair; it is a strategic platform to demonstrate how their technologies and capital can dovetail with China’s policy goals.

Merck’s participation, as reflected in the interview, underscores the company’s awareness that alignment with the 15th Plan is not optional but a prerequisite for sustained growth in the Chinese market. The firm’s articulation of a “long‑term investment strategy” signals a commitment that extends beyond short‑term market opportunism, aiming instead to embed Merck within the structural reforms that the plan envisions.

Merck’s Long‑Term Investment Strategy in China

Janssens described Merck’s investment outlook as “long‑term” and “deeply rooted” in the Chinese market, indicating a strategic posture that anticipates both opportunities and regulatory nuances. While the interview did not disclose specific financial figures, the emphasis on sustained investment suggests that Merck intends to expand its research, development, and production capacities in China over the coming years. This approach aligns with the broader trend among leading multinationals to localise key functions—particularly R&D—to better serve Chinese customers and to tap into the country’s talent pool.

The interview also highlighted Merck’s dual focus on pharmaceutical and life‑science segments, with Janssens noting the importance of “engagement with the country’s innovation ecosystem.” By positioning itself as a partner rather than a mere supplier, Merck signals a willingness to co‑develop technologies with Chinese research institutions, biotech firms, and hospitals. This collaborative stance is consistent with Beijing’s policy push for “open innovation,” which encourages foreign firms to share expertise while also contributing to the domestic knowledge base.

In practical terms, Merck’s strategy likely involves expanding its local manufacturing footprint, enhancing supply‑chain resilience, and deepening its clinical trial networks within China. By embedding these capabilities, the company can respond more swiftly to market demand, comply with evolving regulatory standards, and reduce reliance on cross‑border logistics—a factor that has gained heightened attention in the wake of recent global supply‑chain disruptions.

Integration with China’s Innovation Ecosystem

The interview placed particular emphasis on Merck’s interaction with China’s innovation ecosystem, a term that encompasses universities, research institutes, incubators, and emerging biotech startups. Janssens noted that Merck is “actively engaging” with these actors, reflecting a strategic recognition that breakthroughs in biotechnology increasingly emerge from collaborative networks rather than isolated corporate labs.

China’s policy documents have repeatedly underscored the importance of “dual‑innovation”—the simultaneous development of indigenous technologies and the integration of foreign expertise. By participating in joint research projects, sponsoring academic conferences, and investing in local biotech incubators, Merck can position itself as a catalyst for the next wave of medical innovation. This approach also helps the company navigate the regulatory environment, as partnerships with domestic institutions often facilitate smoother approvals for clinical trials and product registrations.

Moreover, Merck’s engagement with the innovation ecosystem dovetails with the government’s ambition to transform China into a global hub for high‑end biopharma. The 15th Five‑Year Plan calls for the establishment of “national biomedicine innovation centres” and the cultivation of “world‑class” research facilities. Multinational firms that align their R&D pipelines with these national projects stand to benefit from preferential policies, tax incentives, and access to a growing pool of skilled researchers.

The Rising Role of Artificial Intelligence in Biotechnology

A notable theme in the interview was the growing relevance of artificial intelligence (AI) in Merck’s life‑science operations, particularly in the realms of biotechnology and cancer treatment. Janssens described AI as an “enabling technology” that is reshaping drug discovery, diagnostic precision, and personalised therapy. While the interview did not enumerate specific AI platforms, the acknowledgment of its importance signals Merck’s intention to integrate advanced data analytics into its Chinese operations.

China’s policy agenda places AI at the core of its technological upgrade, with the 15th Five‑Year Plan earmarking AI as a key driver of industrial transformation. In the biomedical sector, AI is being deployed to accelerate target identification, optimise clinical trial design, and predict patient outcomes. By aligning its AI initiatives with the national agenda, Merck can leverage government‑supported data infrastructures, such as the national health data platform, to enhance its research efficiency.

The discussion also touched on AI’s role in cancer treatment, a therapeutic area where Merck has historically invested heavily. AI‑assisted imaging, genomics, and treatment planning can improve diagnostic accuracy and enable more precise, personalised interventions. As China seeks to improve its oncology outcomes—particularly in the context of an ageing population and rising cancer incidence—foreign firms that bring sophisticated AI‑driven solutions are likely to find a receptive market and supportive policy environment.

Strategic Implications for Multinational Companies at the CIIE

The timing of Merck’s interview, coinciding with the launch of the CIIE, underscores the expo’s role as a strategic venue for foreign firms to articulate their China strategies. By publicly affirming a long‑term, innovation‑focused investment plan, Merck signals to both Chinese authorities and global investors that it views China as a cornerstone of its growth trajectory.

For other multinational corporations, Merck’s approach offers a template: align corporate objectives with the high‑quality development narrative, deepen engagement with local innovation networks, and integrate cutting‑edge technologies such as AI to meet the evolving demands of Chinese consumers and regulators. Companies that adopt a similar stance are likely to secure a more favourable position in the competitive landscape of China’s pharmaceutical and biotech markets.

Furthermore, the CIIE’s emphasis on “global cooperation” provides an arena for firms to showcase collaborative projects, joint ventures, and technology transfer agreements. Demonstrating tangible contributions to China’s strategic priorities—whether through joint research, talent development, or supply‑chain localisation—can enhance a company’s reputation and potentially unlock policy incentives that the 15th Five‑Year Plan promises to extend to foreign partners.

Future Outlook: Regional Stability, Supply Chains, and Diplomatic Momentum

Merck’s articulated strategy reflects a broader trend of foreign enterprises seeking to embed themselves within China’s high‑quality development framework. This alignment has implications that extend beyond corporate profitability. By fostering deeper technological cooperation, multinational firms can contribute to the stability of regional supply chains, particularly in the pharmaceutical sector where disruptions have global health ramifications.

The integration of AI and advanced biotech within China’s domestic ecosystem also carries strategic weight for global health security. As China expands its capacity for innovative drug development and precision medicine, the international community stands to benefit from accelerated access to novel therapies and shared scientific insights. Conversely, a robust Chinese biotech sector can serve as a buffer against external shocks, reducing reliance on external sources for critical medicines.

Diplomatically, the collaborative narrative promoted at the CIIE and echoed in Merck’s interview supports a constructive trajectory in US‑China relations and broader multilateral engagements. By highlighting mutual interests in health innovation and high‑quality development, such corporate‑state interactions can help to mitigate geopolitical tensions and sustain a climate of pragmatic cooperation.

In sum, Merck China’s strategic positioning—rooted in long‑term investment, deep integration with the national innovation ecosystem, and the deployment of AI in biotech—exemplifies how leading multinationals are interpreting the signals of the 15th Five‑Year Plan. As the CIIE unfolds, the company’s approach will be closely watched as a barometer of foreign confidence in China’s high‑quality development pathway and as a potential catalyst for deeper Sino‑global collaboration in the life‑science arena.

By Prof. Marcus Chen, Staff Writer

This article was produced with AI-assisted research and editorial support. Reporting is based on the source material cited below. Sources: CGTN video report (03 November 2026); CGTN; Global1.News